Pic: maybefalse / E+ via Getty Images
Health & Biotech
Bioactives developer Clover Corporation (ASX:CLV) says an Aussie clinical research study has shown its proprietary Docosahexaenoic Acid (DHA) emulsion (Premneo) improves the IQ of children born prematurely.
The South Australian Health and Medical Research Institute (SAHMRI) trial highlighted that the IQ of children born prematurely improved by 3.5-points and 30% closer to the mean IQ of children born full term, following dietary supplementation with the emulsion.
“Children born prematurely generally have a lower IQ than children born full-term,” MD and CEO Peter Davey said.
“SAHMRI reported that the study has achieved a statistically significant 3.5-point improvement in the mean IQ score of the premature children who received the high DHA supplement, Premneo, compared with those who received a placebo emulsion.
“By supplementing with Premneo until babies reached the equivalent of full term, the study showed for the first time that it is possible to improve IQ through a high DHA emulsion.”
Clover will now turn its attention to the commercialisation of the product.
The company’s 3Dicom MD software has been cleared as a Class II Software-as-a-Medical Device (SaMD) by the United States Food and Drug Administration.
It’s a big milestone, because 510(k) clearance enables commercial launch into United States’ medical imaging software market – which is valued at $USD885.5 million per annum.
The product is designed for use by medical practitioners to collaboratively visualise standard CT/MRI and PET scans in 2D & 3D in real- time with built-in voice and text chat, and remote control functionality.
CLARITY PHARMACEUTICALS (ASX:CU6)
The radiopharmaceutical player has reached the 50% recruitment milestone for its Cu SAR-bisPSMA trial (COBRA) for for patients with prostate cancer in the US.
The company now has 6 sites actively recruiting the remaining participants with suspected recurrence of their prostate cancer across the country.
Executive chairman, Dr Alan Taylor says the company’s Targeted Copper Theranostic platform has the potential to enable patient access to critical treatments that are safe and efficacious, on time and at any treatment centre with a positron emission tomography camera.
“This shows promise of substantially growing the radiopharmaceutical field into the large oncology market, moving towards the big pharma model with ready-to-use products on-demand and minimising logistical hindrances associated with the current generation of products,” he said.
“We believe this advancement will help us reach our goal of improving treatment outcomes for children and adults with cancer by focusing on the needs of the patients and their treating staff.”
The company has been granted a patent in the United States for its novel supercapacitor technology, which is used to produce metal oxide decorated products that show superior performance to existing activated carbon used in supercapacitors.
(For context supercapacitors are used in in cars, buses, trains, cranes and elevators for regenerative braking, short-term energy storage, or burst-mode power delivery.)
And First Graphene has an exclusive worldwide license, enabling it to advance research and development with view to up-scaling to meet industry demand – which is slated to grow from US$409 million in 2020 to US$720 million by 2025 at an expected CAGR of 12%.
The growth of the market is driven by increasing demand in energy harvesting applications and growing use of supercapacitors in trains and aircraft, not to mention increasing global demand for electric vehicles.
The semiconductor stock has successfully completed full technology qualification of its Resistive Random-Access Memory (ReRAM) module – manufactured by its R&D partner CEA-Leti.
It’s kind of a big deal, because it’s a key step that must be completed for every semiconductor product on each new target process.
The qualification was based on industry standards and has demonstrated the quality, repeatability and reliability of Weebit’s ReRAM, and confirmed its suitability for volume production as embedded IP.
The company is now working to extend the qualification to even higher temperatures and endurance levels.
ICE has secured two new orders for its AI software solution from reseller Rasilient, for US state prison end-users, valued at US$56,250 (A$87,800) in aggregate for five year licence terms.
“The prisons market has always offered a particularly strong use-case for icetana’s AI software,” CEO and MD Matt Macfarlane said.
“It is nice to have COVID restrictions behind us so that these expansion orders can be negotiated and implemented in a timely manner.”
The company has launched a new SaaS product, wyde, a platform to automate influencer marketing and integration with Shopify.
Platform users will be provided with an NFT card once active on the wyde network which will store digital information and identity, including reward and loyalty points.
IS3 says the app will allow merchants to seamlessly integrate with the wyde platform in minutes and leverage the Company’s existing and new influencers and users.
The suite of wyde Apps have been submitted to both the Apple App Store (IOS) and the Google Play Store (Android).
Health & Biotech
Health & Biotech
Health & Biotech
